14-[[(1S)-1-carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxopropoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-14-oxotetradecanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 14-[[(1S)-1-carboxy-4-oxo-4-[2-[2-[2-oxo-2-[2-[2-(2-oxopropoxy)ethoxy]ethylamino]ethoxy]ethoxy]ethylamino]butyl]amino]-14-oxotetradecanoic acid
• 化学式: C₃₂H₅₇N₃O₁₂
• 分子量: 675.8
• InChiKey: SRHMVRWMNXQZBH-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  47
• 可旋转键数：
  34
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  216
• 氢给体数：
  5
• 氢受体数：
  12

文献信息

• Novel Insulin Derivatives and the Medical Uses Hereof
  申请人：NOVO NORDISK A/S

  公开号：US20170008945A1

  公开（公告）日：2017-01-12

  The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

  本发明属于与糖尿病相关的医药领域。更具体地说，该发明涉及人类胰岛素类似物的新颖酰化衍生物。该发明还提供包含这种胰岛素衍生物的药物组合物，并涉及使用这种衍生物治疗或预防与糖尿病相关的医疗状况。
• [EN] NOVEL INSULIN DERIVATIVES AND THE MEDICAL USES HEREOF<br/>[FR] NOUVEAUX DÉRIVÉS D'INSULINE ET LEURS UTILISATIONS MÉDICALES
  申请人：NOVO NORDISK AS

  公开号：WO2017032798A1

  公开（公告）日：2017-03-02

  The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

  本发明涉及与糖尿病相关的医疗药物领域。更具体地，该发明涉及人类胰岛素类似物的新型酰化衍生物。该发明还提供了包含这种胰岛素衍生物的药物组合物，并涉及使用这些衍生物治疗或预防与糖尿病相关的医疗状况。
• Insulin derivatives and the medical uses hereof
  申请人：Novo Nordisk A/S

  公开号：US11352406B2

  公开（公告）日：2022-06-07

  The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.

  本发明属于治疗糖尿病药物领域。更具体地说，本发明涉及人胰岛素类似物的新型酰化衍生物。本发明还提供了包含这种胰岛素衍生物的药物组合物，并涉及使用这种衍生物治疗或预防与糖尿病有关的病症。
• ACYLATED GLUCAGON ANALOGUES
  申请人：Zealand Pharma A/S

  公开号：EP3057984B1

  公开（公告）日：2018-07-11
• AN A22K, DESB27, B29R, DES B30, AT EPSILON POSITION OF LYSINE 22 ACYLATED HUMAN INSULIN ANALOGUE
  申请人：Novo Nordisk A/S

  公开号：EP3110840B1

  公开（公告）日：2020-10-21